Skip to main content
NCBI home page
Journal of Clinical Medicine logoLink to Journal of Clinical Medicine
. 2020 Jun 14;9(6):1856. doi: 10.3390/jcm9061856

Chronic Gastritis Is Associated with a Decreased High-Density Lipid Level: Histological Features of Gastritis Based on the Updated Sydney System

Dong-Hoon Kim 1, Byoung Kwan Son 2, Kyueng-Whan Min 3,*, Sang Kuk Han 4,*, Ji Ung Na 4, Pil Cho Choi 4, Hack-Lyoung Kim 5, Mi Jung Kwon 6, Young Ha Oh 3, Woon Yong Jung 3, Ji-Yong Moon 7, Sangmo Hong 8, Ki-Wook Oh 9, Young Seo Kim 9
PMCID: PMC7355915  PMID: 32545889

Abstract

Chronic gastritis could activate a systemic inflammatory response that could result in adverse lipid profiles. To determine the severity of chronic gastritis, Helicobacter pylori (HP), mononuclear cell (lymphocytes and plasma cells), and neutrophil scores were assessed on the basis of the updated Sydney system (USS), which is widely used for histological grading. The aim of this study was to assess the relationships between gastric histological features and lipid profile levels. This study included 15,322 males and 5929 females who underwent a health checkup and gastric biopsy at the Kangbuk Samsung Medical Center (KBSMC). We analyzed whether the HP, mononuclear cell, and neutrophil grades according to the USS were related to serum leukocyte count, unhealthy behaviors, and lipid profile levels. Gastritis with HP, neutrophils, or moderate to severe mononuclear cells was associated with an elevated serum leukocyte count. A high leukocyte count was related to increased low-density lipoproteins (LDL) and triglycerides/very-low-density lipoprotein (VLDL) and decreased high-density lipoproteins (HDL). In multivariate analyses, chronic gastritis with HP or moderate to severe mononuclear cells was significantly associated with decreased HDL in males, while mononuclear cells were significantly related to decreased HDL in females. Chronic gastritis was associated with an increased systemic inflammatory response, which was associated with unfavorable lipid profiles, especially low HDL levels.

Keywords: Helicobacter, cholesterol, gastritis, cardiovascular diseases

1. Introduction

Dyslipidemia, such as increased low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and triglyceride (TG) levels and decreased high-density lipoprotein (HDL) levels, is associated with a high incidence of metabolic syndrome and cardiovascular disease (CVD) [1,2]. Previous studies have demonstrated that lipid metabolism can be affected by alcohol consumption, diabetes, and hormonal imbalance as well as systemic inflammation and neoplasms [3,4]. Moreover, systemic inflammation with hypercholesterolemia can play an important role in the development of atherosclerosis [5].

Helicobacter pylori (HP) is a Gram-negative bacterium that colonizes the acidic gastric mucosa and causes chronic gastritis, ulcers, and cancer [6]. HP induces the recruitment of inflammatory cells such as neutrophils and mononuclear cells (lymphocytes and plasma cells) to the gastric mucosa [7]. Increased mononuclear cells in response to HP infection could induce the secretion of proinflammatory cytokines, leading to systemic inflammation such as elevated serum leukocyte count [8]. Another study suggested that the crosstalk between systemic inflammation and lipid metabolism has some effect on the alteration of lipids in the context of chronic gastritis [9]. Another study reported that HP was related to elevated levels of total cholesterol, LDL, lipoprotein(a), apolipoprotein B, and TGs, and decreased levels of HDL and apolipoprotein A-1 in the blood [10,11].

The updated Sydney system (USS), known as an objective grading system, is widely used to evaluate the severity of gastritis and includes the following elements: HP, neutrophils, mononuclear cells, atrophy, and intestinal metaplasia [12]. The USS scores are based on histological findings of gastric mucosal tissue. The USS is a more valuable grading system because it can represent not only the grade of HP but also that of neutrophils and mononuclear cells. Thus, each element of the USS can be used to quantitatively assess the effect of gastritis on lipid metabolism.

This study was conducted with people who underwent a large-scale gastroscopic biopsy and health checkup and is the first study to assess relationships between the histological features of gastritis and serum lipid profile levels. There have been several studies conducted on HP and lipid profiles, and the results of these studies have the following limitations: A small number of cases, analyses of relationships between carbon-13 urea (urea breath test) and cytotoxin-associated gene A (CagA), the use of indirect markers of HP and lipid profiles, and the use of serum samples [13,14].

The purpose of this study was to investigate whether the histological grading of local gastritis based on the USS could affect systemic homeostasis, such as lipid profiles and leukocyte levels in serum, or be associated with harmful lifestyle habits in a total of 21,251 people, including 15,322 males and 5929 females.

2. Materials and Methods

2.1. Patient Selection

We recruited 21,600 individuals who underwent a gastroscopy and histological examination during their health checkup (workplace health checkups) at the Kangbuk Samsung Medical Center (KBSMC) from 1 August 2006 to 30 September 2009 (excluding patients aged younger than 18 years). Patients with >2 mm-sized specimens and known clinical and laboratory parameters were included. A total of 349 patients were excluded based on the following criteria: (1) People who had a history of HP eradication or gastric surgery; (2) those who had already received anti-cholesterol therapy; (3) those suffering from severe liver disease, severe kidney disease, or cancer; and (4) those who had inadequate clinical and laboratory data. A total of 21,251 patients were included in the study. Gastric mucosal tissues from gastroscopic biopsy were assessed based on the USS [12].

2.2. Data Collection

The clinical and laboratory data collected from patients’ medical records included underlying diseases, medical history, exercise habits, and alcohol consumption. Systolic/diastolic blood pressure (SBP/DBP), body weight, and height were measured by a trained nurse. The body mass index (BMI) was calculated by dividing the body weight in kilograms (kg) by height in meters squared (m2). Regular exercise was defined as exercising for a minimum of 30 min three days a week. Alcohol consumption was defined as the consumption of alcohol at least once per week. Hypertension was defined as an SBP of ≥140 mmHg, a DBP of ≥90 mmHg, or a history of anti-hypertensive therapy. Serum biochemical profiles were measured, including total cholesterol, LDL, VLDL, TGs, HDL, and serum leukocyte count.

The Laboratory Medicine Department at KBSMC in Seoul, Korea, is accredited by the Korean Society of Laboratory Medicine and the Korean Association of Quality Assurance for Clinical Laboratories. The laboratory participated in the College of American Pathologists Survey Proficiency Testing.

2.3. Microscopic Examination for Updated Sydney System Scoring

The specimens were fixed in 10% formalin, embedded in paraffin on the oriented edge, and cut into 4-µm-thick sections. All sections were stained with hematoxylin-eosin and Giemsa stain for histopathological evaluation. We assessed histological features of gastritis in gastric mucosa using a light microscope in a blinded fashion. According to the USS based on HP, neutrophils, mononuclear cells, atrophy, and intestinal metaplasia, we evaluated the following three elements: HP, mononuclear cells, and neutrophils [12]. The density of each element was recorded separately as follows: 0 (absence), 1 (mild), 2 (moderate), and 3 (severe) (Figure 1A). The grading of HP, mononuclear cells, and neutrophils is based on the highest possible density if two or more biopsy tissues are available (HP: Absence, 10,361 (48.8%); mild, 4438 (20.9%); moderate, 4532 (21.3%); severe, 1920 (9%)) (mononuclear cell: Absence, 336 (1.6%); mild, 7282 (34.2%); moderate, 12,286 (57.8%); severe, 1347 (6.3%)) (neutrophil: Absence, 5556 (26.1%); mild, 4929 (23.2%); moderate, 8388 (39.5%); severe, 2378 (11.2%)). HP, mononuclear cells, and neutrophils were each divided into two groups as follows: Presence of HP vs. absence of HP, absence of mononuclear cells and mild mononuclear cells vs. moderate/severe mononuclear cells, and presence of neutrophils vs. absence of neutrophils.

Figure 1.

Figure 1

Open in a new tab

(A) Mild (score 1), moderate (score 2), and severe (score 3) Helicobacter pylori (red arrowhead) (Giemsa, original magnification ×400), mononuclear cells (hematoxylin and eosin, original magnification ×100), and neutrophils (hematoxylin and eosin, original magnification ×100) (B) The presence of Helicobacter pylori is associated with higher mononuclear cell (right) and neutrophil (left) counts than the absence of Helicobacter pylori (mononuclear cells: 1.34 and 2.02, respectively, p < 0.001; neutrophils: 0.7 and 1.99, respectively, p < 0.001).

2.4. Statistical Analysis

Correlations between clinical laboratory parameters and grade of gastritis, including HP, mononuclear cells, and neutrophils, were analyzed using the chi-square test, Student’s t-test, and Pearson correlation coefficient. Coefficients between gastritis and lipid profile levels, such as LDL, TGs, LDL and VLDL, were tested with multiple binary logistic analyses after adjustment for the following confounders: Age, body mass index (BMI), smoking, exercise rate, and alcohol consumption; p-values less than 0.05 were considered statistically significant. Statistical analyses were conducted using IBM SPSS Statistics for Windows, version 24.0 (IBM, Corp., Armonk, NY, USA) and R package.

3. Results

3.1. Clinical and Laboratory Parameters According to Helicobacter Pylori, Mononuclear Cells, and Neutrophils

HP was associated with increased mononuclear cells and neutrophils (mononuclear cell score, 1.34 and 2.02, respectively, p < 0.001; neutrophil score, 0.7 and 1.99, respectively, p < 0.001) (Figure 1B). Mononuclear cells were associated with high SBP and DBP (p < 0.001 and p = 0.001, respectively).

Among the 10,361 people without HP, moderate/severe mononuclear cells were associated with high BMI, smoking, alcohol consumption, high SBP/DBP, and increased leukocyte count in the male group (all p < 0.05). Neutrophil was related to old age and increased leukocyte count in the male group (all p < 0.05). In the female group, moderate/severe mononuclear cells were associated with old age, high BMI, high SBP, and increased leukocyte count (all p < 0.05). Neutrophil was related to old age, high BMI, smoking, and high SBP/DBP in the female group (all p < 0.05). There were significant relationships between moderate/severe mononuclear cells and unfavorable lipid profile levels in the female group. (all p < 0.05).

In the 10,980 people with HP, moderate/severe mononuclear cells were associated with young age, diabetes, and high SBP in the male group (all p < 0.05). There was a relationship between neutrophil and young age in the male and female groups (all p < 0.05). Moderate/severe mononuclear cells were associated with young age and low HDL in the female group (all p < 0.05) (Table 1).

Table 1.

Comparison of clinical laboratory parameters according to mononuclear cells and neutrophils in 10,361 people without Helicobacter pylori and 10,890 people with Helicobacter pylori using updated Sydney system.

Absence of Helicobacter pylori (N = 10,361)
Parameters Male (n = 15,322) Female (n = 5929)
Mononuclear cell Neutrophil Mononuclear cell Neutrophil
Absence/
Mild (n = 4511)		 Moderate/
Severe (n = 2671)		 p Absence (n = 3459) Presence (n = 3723) p Absence/
Mild (n = 2087)		 Moderate/
Severe (n = 1092)		 p Absence (n = 1610) Presence (n = 1569) p
Clinical
Age, years 44.4 ± 9.8 44.7 ± 9.9 0.23 * 44.2 ± 9.6 44.7 ± 10 0.041 * 44.5 ± 10.5 46.8 ± 11.2 <0.001 * 44.5 ± 10.6 46.1 ± 11 <0.001 *
Body mass index (kg/m2) 24.6 ± 2.8 24.7 ± 2.8 0.009 * 24.6 ± 2.8 24.7 ± 2.8 0.076 * 22.8 ± 3 23.1 ± 3.3 0.007 * 22.8 ± 3.1 23.1 ± 3.2 0.002 *
‡ Regular exercise, % 1259 (27.9) 791 (29.6) 0.129 † 954 (27.6) 1096 (29.4) 0.086 † 552 (26.4) 297 (27.2) 0.681 † 422 (26.2) 427 (27.2) 0.549 †
Cigarette smoking, % 3428 (76) 2048 (76.7) 0.529 † 2621 (75.8) 2855 (76.7) 0.379 † 256 (12.3) 151 (13.8) 0.232 † 184 (11.4) 223 (14.2) 0.022 †
§ Alcohol consumption, % 3694 (81.9) 2236 (83.7) 0.05 † 2840 (82.1) 3090 (83.0) 0.334 † 703 (33.7) 379 (34.7) 0.59 † 563 (35) 519 (33.1) 0.277 †
Hypertension, % 1111 (24.6) 678 (25.4) 0.492 † 864 (25) 925 (24.8) 0.918 † 355 (17) 182 (16.7) 0.845 † 264 (16.4) 273 (17.4) 0.48 †
Diabetes, % 257 (5.7) 150 (5.6) 0.927 † 181 (5.2) 226 (6.1) 0.138 † 75 (3.6) 39 (3.6) 0.999 † 59 (3.7) 55 (3.5) 0.884 †
Hepatitis, % 681 (10.3) 366 (9.7) 0.351 † 489 (9.6) 558 (10.5) 0.138 † 187 (9) 116 (10.6) 0.146 † 139 (8.6) 164 (10.5) 0.092 †
SBP, mmHg 117.5 ± 12.5 118.2 ± 12.7 0.027 * 117.8 ± 12.7 117.7 ± 12.5 0.675 * 111.5 ± 13.6 112.9 ± 14.1 0.006 * 111.1 ± 13.7 112.9 ± 13.9 <0.001 *
DBP, mmHg 76.2 ± 8.6 76.7 ± 8.7 0.013 * 76.4 ± 8.6 76.3±8.7 0.677 * 72.3 ± 9.4 73.0 ± 9.2 0.072 * 72.2 ± 9.3 73.0 ± 9.4 0.018 *
Laboratory
HDL, mg/dL 50.9 ± 11.2 50.5 ± 11 0.129 * 50.8 ± 11.3 50.7 ± 11.1 0.8 * 59.5 ± 13.6 58.2 ± 12.8 0.008 * 59.2 ± 13.4 58.8 ± 13.3 0.378 *
LDL, mg/dL 117.8 ± 30.0 118.8 ± 29.6 0.183 * 118.0 ± 29.6 118.4 ± 30.1 0.557 * 108.6 ± 31.2 111.5 ± 30.6 0.012 * 109.8 ± 31.1 109.4 ± 30.9 0.768 *
Triglycerides, mg/dL 148.9 ± 0.9 152.9 ± 93.5 0.073 * 148.8 ± 89.2 151.8 ± 94.3 0.176 * 101.9 ± 61.5 104.9 ± 61.5 0.2 * 102.4 ± 60.2 103.5 ± 62.8 0.606 *
VLDL, mg/dL 29.8 ± 18.2 30.6 ± 18.7 0.073 * 29.8 ± 17.8 30.4 ± 18.9 0.176 * 20.4 ± 12.3 21.0 ± 12.3 0.2 * 20.5 ± 12.0 20.7 ± 12.6 0.606 *
Leukocyte count (109/L) 6.4 ± 1.7 6.5 ± 1.7 <0.001 * 6.4 ± 1.6 6.5 ± 1.7 0.001 * 5.6 ± 1.5 5.7 ± 1.5 0.04 * 5.6 ± 1.5 5.7 ± 1.5 0.254 *
Presence of Helicobacter pylori (N = 10,890)
Parameters Male (n = 15,322) Female (n = 5929)
Mononuclear cell Neutrophil Mononuclear cell Neutrophil
Absence/
Mild (n = 740)		 Moderate/
Severe (n = 7400)		 p Absence (n = 352) Presence (n = 7788) p Absence/
Mild (n = 280)		 Moderate/
Severe (n = 2470)		 p Absence (n = 135) Presence (n = 2615) p
Clinical
Age, years 43.8 ± 9.2 42.2 ± 8.6 <0.001 * 44.3 ± 9.2 42.3 ± 8.6 <0.001 * 46.1 ± 10.2 44.3 ± 9.8 0.003 * 46.1 ± 10.5 44.4 ± 9.8 0.042 *
Body mass index (kg/m2) 24.8 ± 2.8 24.7 ± 2.8 0.076 * 24.7 ± 2.7 24.7 ± 2.8 0.974 * 22.8 ± 2.9 23.0 ± 3.1 0.461 * 23.0 ± 2.8 23.0 ± 3.1 0.922 *
‡Regular exercise, % 202 (27.3) 1877 (25.4) 0.269 † 89 (25.3) 1990 (25.6) 0.96 † 76 (27.1) 651 (26.4) 0.833 † 34 (25.2) 693 (26.5) 0.812 †
Cigarette smoking, % 570 (77) 5795 (78.3) 0.447 † 267 (75.9) 6098 (78.3) 0.307 † 29 (10.4) 358 (14.5) 0.073 † 14 (10.4) 373 (14.3) 0.254 †
§Alcohol consumption, % 631 (85.3) 6298 (85.1) 0.949 † 296 (84.1) 6633 (85.2) 0.631 † 108 (38.6) 922 (37.3) 0.732 † 59 (43.7) 971 (37.1) 0.148 †
Hypertension, % 161 (21.8) 1657 (22.4) 0.727 † 94 (26.7) 1724 (22.1) 0.05 † 45 (16.1) 395 (16) 0.999 † 28 (20.7) 412 (15.8) 0.155 †
Diabetes, % 53 (7.2) 365 (4.9) 0.011 † 22 (6.2) 396 (5.1) 0.398 † 5 (1.8) 84 (3.4) 0.204 † 3 (2.2) 86 (3.3) 0.665 †
Hepatitis, % 89 (12) 772 (10.4) 0.2 † 36 (10.2) 825 (10.6) 0.897 † 27 (9.6) 247 (10) 0.933 † 13 (9.6) 261 (10) 0.999 †
SBP, mmHg 116.4 ± 12.6 117.6 ± 12.1 0.01 * 117.1 ± 13.3 117.5 ± 12.1 0.584 * 111.3 ± 13.9 111.7 ± 13.8 0.647 * 111.9 ± 15.7 111.7 ± 13.7 0.908 *
DBP, mmHg 76.3 ± 8.2 76.4 ± 8.6 0.814 * 77.0 ± 9.1 76.4 ± 8.5 0.191 * 72.1 ± 9.6 72.0 ± 9.4 0.955 * 72.0 ± 10.2 72.0 ± 9.4 0.954 *
Laboratory
HDL, mg/dL 51.0 ± 11.1 50.3 ± 10.7 0.084 * 50.0 ± 11.0 50.3 ± 10.8 0.598 * 61.2 ± 14.5 58.9 ± 12.9 0.012 * 61.0 ± 13.4 59.0 ± 13 0.076 *
LDL, mg/dL 118.2 ± 29.9 118.6 ± 29.8 0.72 * 116.6 ± 27.3 118.7 ± 29.9 0.172 * 110.7 ± 29.2 110.0 ± 30.6 1.726 * 111.8 ± 29.7 110.0 ± 30.5 1.499 *
Triglycerides, mg/dL 154.9 ± 101.8 153.1 ± 96.4 0.66 * 152.8 ± 102.3 153.3 ± 96.6 0.918 * 103.0 ± 70.9 102.5 ± 60 0.914 * 100.5 ± 63.4 102.7 ± 61.1 0.692 *
VLDL, mg/dL 31.0 ± 20.4 30.6 ± 19.3 0.66 * 30.6 ± 20.5 30.7 ± 19.3 0.918 * 20.6 ± 14.2 20.5 ± 12.0 0.914 * 20.1 ± 12.7 20.5 ± 12.2 0.692 *
Leukocyte count (109/L) 51.0 ± 11.1 50.3 ± 10.7 0.084 * 50.0 ± 11.0 50.3 ± 10.8 0.598 * 5.8 ± 1.4 5.9 ± 1.5 0.206 * 5.8 ± 1.5 5.9 ± 1.5 0.278 *
Open in a new tab

SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; Values are expressed as the mean ± standard deviation or number. * Student’s t-test; † Chi-square test; ‡ Regular exercise is defined as exercising 3 or more days per week; § Alcohol consumption is defined as consuming alcohol at least once per week; p < 0.05 is shown in bold.

In the 15,322 males, HP, neutrophils, and moderate/severe mononuclear cells were associated with young age, smoking, and increased leukocyte count (all p < 0.05). HP and moderate/severe mononuclear cells were related to low exercise rate and alcohol intake (all p < 0.05). VLDL and TGs were increased in individuals with neutrophils and moderate/severe mononuclear cells (all p < 0.05). Among the 5929 females, HP, neutrophils, and moderate/severe mononuclear cells were associated with increased leukocyte counts (all p < 0.001). Neutrophils and moderate/severe mononuclear cells were related to high BMI and smoking (all p < 0.05). LDL was increased while HDL was decreased in moderate/severe mononuclear cells (all p < 0.05) (Table 2).

Table 2.

Comparison of clinicolaboratory parameters according to Helicobacter pylori, mononuclear cells and neutrophils in the group of 15,322 males and the group of 5929 females using updated Sydney system.

Male (n = 15,322)
Parameters Helicobacter pylori Mononuclear Cell Neutrophil
Absence (n = 7182) Presence (n = 8140) p Absence/Mild (n = 5251) Moderate/Severe (n = 10,071) p Absence (n = 3811) Presence (n = 11,511) p
Clinical
Age, years 44.5 ± 9.8 42.4 ± 8.7 <0.001 * 44.3 ± 9.7 42.9 ± 9 <0.001 * 44.3 ± 9.6 43.1 ± 9.2 <0.001 *
Body mass index (kg/m2) 24.6 ± 2.8 24.7 ± 2.8 0.337 * 24.6 ± 2.8 24.7 ± 2.8 0.112 * 24.6 ± 2.8 24.7 ± 2.8 0.056 *
‡ Regular exercise 1905 (26.5) 1893 (23.3) <0.001 † 1374 (26.2) 2424 (24.1) 0.005 † 985 (25.8) 2813 (24.4) 0.085 †
Cigarette smoking 5476 (76.2) 6365 (78.2) 0.004 † 3998 (76.1) 7843 (77.9) 0.016 † 2888 (75.8) 8953 (77.8) 0.011 †
§ Alcohol consumption 5930 (82.6) 6929 (85.1) <0.001 † 4325 (82.4) 8534 (84.7) <0.001 † 3136 (82.3) 9723 (84.5) 0.002 †
Hypertension 1789 (24.9) 1818 (22.3) <0.001 † 1272 (24.2) 2335 (23.2) 0.156 † 958 (25.1) 2649 (23) 0.008 †
Diabetes 407 (5.7) 418 (5.1) 0.156 † 310 (5.9) 515 (5.1) 0.044 † 203 (5.3) 622 (5.4) 0.888 †
Hepatitis 744 (10.4) 861 (10.6) 0.679 † 583 (11.1) 1022 (10.1) 0.071 † 386 (10.1) 1219 (10.6) 0.438 †
SBP, mmHg 117.7 ± 12.6 117.5 ± 12.2 0.205 * 117.3 ± 12.5 117.7 ± 12.3 0.049 * 117.7 ± 12.8 117.6 ± 12.3 0.446 *
DBP, mmHg 76.3 ± 8.6 76.4 ± 8.6 0.695 * 76.2 ± 8.6 76.5 ± 8.6 0.039 * 76.4 ± 8.6 76.4 ± 8.6 0.563 *
Laboratory
HDL, mg/dL 50.7 ± 11.2 50.3 ± 10.8 0.02 * 50.9 ± 11.2 50.3 ± 10.8 0.002 * 50.7 ± 11.2 50.5 ± 10.9 0.234 *
LDL, mg/dL 118.2 ± 29.8 118.6 ± 29.8 0.408 * 117.9 ± 30 118.6 ± 29.7 0.12 * 117.8 ± 29.4 118.6 ± 30 0.189 *
Triglycerides, mg/dL 150.4 ± 91.9 153.3 ± 96.9 0.054 * 149.7 ± 92.5 153.1 ± 95.6 0.035 * 149.2 ± 90.5 152.8 ± 95.9 0.035 *
VLDL, mg/dL 30.1 ± 18.4 30.7 ± 19.4 0.054 * 29.9 ± 18.5 30.6 ± 19.1 0.035 * 29.8 ± 18.1 30.6 ± 19.2 0.035 *
Leukocyte count (109/L) 6.4 ± 1.7 6.6 ± 1.6 <0.001 * 6.4 ± 1.7 6.6 ± 1.6 <0.001 * 6.4 ± 1.7 6.5 ± 1.6 <0.001 *
Female (n = 5929)
Parameters Helicobactor pylori Mononuclear cell Neutrophil
Absence (n = 3179) Presence (n = 2750) p Absence/Mild (n = 2367) Moderate/Severe (n = 3562) p Absence (n = 1745) Presence (n = 4184) p
Clinical
Age, years 45.3 ± 10.8 44.5 ± 9.8 0.002 * 44.7 ± 10.5 45.0 ± 10.3 0.207 * 44.6 ± 10.6 45.0 ± 10.3 0.229 *
Body mass index (kg/m2) 22.9 ± 3.1 23.0 ± 3.1 0.704 * 22.8 ± 3 23.0 ± 3.2 0.012 * 22.8 ± 3 23.0 ± 3.1 0.007 *
‡ Regular exercise 807 (25.4) 694 (25.2) 0.919 † 603 (25.5) 898 (25.2) 0.842 † 436 (25) 1065 (25.5) 0.73 †
Cigarette smoking 407 (12.8) 387 (14.1) 0.163 † 285 (12.0) 509 (14.3) 0.014 † 198 (11.3) 596 (14.2) 0.003 †
§ Alcohol consumption 1082 (34.0) 1030 (37.5) 0.007 † 811 (34.3) 1301 (36.5) 0.08 † 622 (35.6) 1490 (35.6) 0.999 †
Hypertension 537 (16.9) 440 (16) 0.374 † 400 (16.9) 577 (16.2) 0.499 † 292 (16.7) 685 (16.4) 0.761 †
Diabetes 114 (3.6) 89 (3.2) 0.505 † 80 (3.4) 123 (3.5) 0.937 † 62 (3.6) 141 (3.4) 0.783 †
Hepatitis 303 (9.5) 274 (10) 0.606 † 214 (9.0) 363 (10.2) 0.156 † 152 (8.7) 425 (10.2) 0.096 †
SBP, mmHg 112.0 ± 13.8 111.7 ± 13.8 0.401 * 111.5 ± 13.7 112.1 ± 13.9 0.095 * 111.2 ± 13.8 112.2 ± 13.8 0.014 *
DBP, mmHg 72.6 ± 9.3 72.0 ± 9.4 0.033 * 72.3 ± 9.4 72.3 ± 9.3 0.961 * 72.2 ± 9.3 72.4 ± 9.4 0.395 *
Laboratory
HDL, mg/dL 59.0 ± 13.3 59.1 ± 13.1 0.856 * 59.7 ± 13.7 58.7 ± 12.8 0.004 * 59.4 ± 13.4 58.9 ± 13.1 0.233 *
LDL, mg/dL 109.6 ± 31 110.1 ± 30.4 0.531 * 108.9 ± 30.9 110.5 ± 30.6 0.044 * 109.9 ± 31.0 109.8 ± 30.6 0.888 *
Triglycerides, mg/dL 102.9 ± 61.5 102.6 ± 61.2 0.815 * 102.0 ± 62.6 103.2 ± 60.5 0.466 * 102.2 ± 60.5 103.0 ± 61.7 0.67 *
VLDL, mg/dL 20.6 ± 12.3 20.5 ± 12.2 0.815 * 20.4 ± 12.5 20.6 ± 12.1 0.466 * 20.4 ± 12.1 20.6 ± 12.3 0.67 *
Leukocyte count (109/L) 5.7 ± 1.5 5.9 ± 1.5 <0.001 * 5.7 ± 1.5 5.9 ± 1.5 <0.001 * 5.6 ± 1.5 5.8 ± 1.5 <0.001 *
Open in a new tab

BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. Values are expressed as the mean ± standard deviation or number. * Student’s t-test; † Chi-square test; ‡ Regular exercise is defined as exercising 3 or more days per week; § Alcohol consumption is defined as consuming alcohol at least once per week; p < 0.05 is shown in bold.

In multivariate analyses, after adjustment for confounders such as age, BMI, smoking, exercise rate, and alcohol consumption, gastritis with HP or mononuclear cells was significantly associated with low HDL levels in males (all p < 0.05). In females, low HDL was statistically related to gastritis with mononuclear cells (all p < 0.05) (Table 3).

Table 3.

Multivariate binary logistic analyses of LDL, VLDL, triglycerides and HDL according to Helicobacter pylori, mononuclear cells and neutrophils using updated Sydney system (USS).

Parameters Male (n = 15,322) Female (n = 5929)
Odds Ratio 95% CI p Odds Ratio 95% CI p
Low High Low High
HDL
(<60 mg/dL)		 HP
Crude 0.892 0.822 0.968 0.006 0.966 0.871 1.07 0.505
*Adjusted 0.898 0.826 0.977 0.012 0.926 0.832 1.029 0.154
Mononuclear cell
Crude 0.904 0.83 0.984 0.02 0.891 0.802 0.989 0.03
*Adjusted 0.913 0.837 0.997 0.042 0.888 0.798 0.99 0.032
Neutrophil
Crude 0.942 0.858 1.034 0.21 0.93 0.831 1.041 0.206
*Adjusted 0.95 0.864 1.045 0.295 0.946 0.843 1.063 0.35
LDL
(>130 mg/dL)		 HP
Crude 1.027 0.96 1.098 0.44 1.07 0.949 1.207 0.267
*Adjusted 1.026 0.958 1.098 0.462 1.141 1.007 1.292 0.038
Mononuclear cell
Crude 1.043 0.972 1.12 0.238 1.088 0.962 1.23 0.179
*Adjusted 1.037 0.966 1.114 0.314 1.072 0.944 1.217 0.283
Neutrophil
Crude 1.05 0.971 1.135 0.22 0.999 0.876 1.139 0.987
*Adjusted 1.044 0.965 1.129 0.28 0.973 0.849 1.115 0.692
Triglycerides
(>150 mg/dL)		 HP
Crude 1.06 0.993 1.131 0.081 1.043 0.905 1.203 0.56
*Adjusted 1.039 0.971 1.112 0.265 1.134 0.977 1.317 0.098
Mononuclear cell
Crude 1.058 0.988 1.133 0.108 1.11 0.959 1.284 0.162
*Adjusted 1.032 0.961 1.108 0.391 1.084 0.931 1.263 0.3
Neutrophil
Crude 1.004 0.859 1.173 0.963 1.078 1.000 1.163 0.05
*Adjusted 1.054 0.975 1.140 0.185 0.961 0.816 1.132 0.636
VLDL
(>30 mg/dL)		 HP
Crude 1.060 0.993 1.131 0.081 1.043 0.905 1.203 0.56
*Adjusted 1.039 0.971 1.112 0.265 1.134 0.977 1.317 0.098
Mononuclear cell
Crude 1.058 0.988 1.133 0.108 1.11 0.959 1.284 0.162
*Adjusted 1.032 0.961 1.108 0.391 1.084 0.931 1.263 0.3
Neutrophil
Crude 1.078 1.000 1.163 0.05 1.004 0.859 1.173 0.963
*Adjusted 1.054 0.975 1.14 0.185 0.961 0.816 1.132 0.636
Open in a new tab

HP, Helicobacter pylori; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; *Adjusted for age, body mass index, smoking, exercise and alcohol consumption; p < 0.05 is shown in bold.

3.2. Associations among Helicobacter Pylori, Mononuclear Cells, Neutrophils, Serum Leukocyte Count and Lipid Profiles

We explored whether serum leukocyte counts reflected systemic inflammatory effects on HP, mononuclear cells, and neutrophils and their subsequent effects on serum lipid profiles. First, we analyzed the relationships between the grade of HP, mononuclear cells, neutrophils, and serum leukocyte count. In the analyses of the female group and the male group, a high serum leukocyte count was found to be elevated in individuals with gastritis associated with HP, neutrophils and mononuclear cells (female: HP (absence vs. presence), 5.66 (109/L) vs. 5.92; mononuclear cells (absence/mild vs. moderate/severe), 5.65 vs. 5.87; neutrophils (absence vs. presence), 5.65 vs. 5.84, male: HP, 6.44 vs. 6.57; mononuclear cells, 6.41 vs. 6.56; neutrophils, 6.39 vs. 6.55, all p < 0.001) (Figure 2). Second, we analyzed the relationships between serum leukocyte counts and lipid levels. In the analyses of the female group and the male group, the Pearson coefficient showed good correlation between high leukocyte count and lipid levels (female: HDL, r = −0.134; LDL, r = 0.148; triglycerides, r = 0.238; VLDL, r = 0.238, male: HDL, r = −0.139; LDL, r = 0.113; triglyceride, r = 0.204; VLDL, r = 0.204; all p < 0.001) (Figure 3), suggesting that systemic inflammation had a significant effect on lipid metabolism These results demonstrated that the severity of gastritis could be associated with elevated lipid profile levels.

Figure 2.

Figure 2

Open in a new tab

(A) In the female group, the serum leukocyte count was increased in the presence of Helicobacter pylori (absence, 5.66 versus presence, 5.92 (109/L)]), mononuclear cells (absence/mild, 5.65 versus moderate/severe 5.82 (109/L)), and neutrophils (absence, 5.65 versus presence, 5.84 (109/L)). (B) In the male group, the serum leukocyte count was increased in the presence of Helicobacter pylori (absence, 6.44 versus presence, 6.57 (109/L)), mononuclear cells (absence/mild, 6.41 versus moderate severe 6.56 (109/L)), and neutrophils (absence, 6.39 versus presence, 6.55 (109/L)) (error bars: standard errors of the mean).

Figure 3.

Figure 3

Open in a new tab

(A) In the female group, a high serum leukocyte count was associated with decreased high-density lipoprotein (HDL) but increased low-density lipoprotein (LDL), triglycerides and very-low-density lipoprotein (VLDL) (HDL, r = −0.134; LDL, r = 0.148; triglycerides, r = 0.238; VLDL, r = 0.238, all p < 0.001). (B) In the male group, a high serum leukocyte count was associated with decreased high-density lipoprotein (HDL) but increased low-density lipoprotein (LDL), triglycerides and very-low-density lipoprotein (VLDL) (HDL, r = - 0.139; LDL, r = 0.113; triglycerides, r = 0.204; VLDL, r = 0.204, all p < 0.001).

4. Discussion

In our study, gastritis with HP, neutrophils, and mononuclear cells was associated with unfavorable lipid profile levels, including increased LDL/VLDL/TGs and decreased HDL, as well as unhealthy behaviors, such as decreased exercise rate, history of smoking, and increased alcohol intake. In people without HP, neutrophils and mononuclear cells were related to unfavorable lipid profile levels, whereas in people with HP, there was a correlation between mononuclear cells and low HDL. We found that mononuclear cell and neutrophilic infiltration independent of HP could affect lipid metabolism in people with gastritis. Chronic gastritis was associated with a high serum leukocyte count representing an increased systemic inflammatory response in the female and the male groups. Interestingly, there was a positive correlation between high leukocyte count and increased LDL/VLDL/TGs and decreased HDL. These results demonstrated that histological features of gastritis could be associated with elevated lipid profile levels. In multivariate analyses, chronic gastritis with mononuclear cells was significantly related to low HDL in both the male and female groups, while chronic gastritis with HP was significantly associated with low HDL in the male group.

Epidemiological surveys have indicated that the possible pathological consequences of HP infection are not restricted to the gastroduodenal tract [15,16,17]. Helicobacter gastritis is correlated with a wide range of extradigestive diseases, such as heart, vessel, skin, endocrine, respiratory, hematopoietic, immune, and central nervous system conditions [18,19]. CVD risk was more closely related to HP infection than to other clinical diseases. Previous studies have reported a relationship between HP and atherosclerosis, which is explained by the immune cross-reactivity between CagA (HP virulence factor) and the arterial wall [20,21]. CagA could enhance immune-related cytokine production, which increases systemic inflammatory responses such as increased leukocyte counts [22]. Indeed, higher leukocyte counts are associated with an increased incidence of CVD, stroke, and sudden death [23].

USS is accepted worldwide as the gold standard for the histopathological assessment of gastritis. USS scoring is based on five elements, namely, HP, chronicity (monocytic infiltration), activity (neutrophilic infiltration), glandular atrophy, and intestinal metaplasia. Published data described that HP and inflammatory cell infiltration increase CVD risk [24]. The assessment of the severity of gastritis based on HP, mononuclear cells, and neutrophils should be focused not only on local inflammation but also on the whole body. Previous studies suggested that HP was related to unfavorable lipid profile levels, hypercoagulation, and endothelial dysfunction as a result of high homocysteine levels, an increase in vasoconstrict factors and the stimulation of platelet aggregation and then the development of atherosclerotic plaques through the action of reactive oxygen species and circulating lipid peroxides [25,26,27]. The accumulation of lipids within the arterial wall in the context of the HP infection-related systemic inflammatory response could lead to the development of atherosclerosis with vessel wall injury and may contribute to increased susceptibility to myocardial infarction [28,29,30]. A high serum leukocyte count associated with local gastritis could generate inflammatory mediators, cytokines, and oxygen-free radicals, which result in cardiac damage [31]. A study by Takeshita et al. demonstrated that increased systemic inflammation could induce ischemic heart disease [32]. Our study revealed that chronic gastritis, similar to local inflammatory processes, plays an important role in high leukocyte count, increased LDL/VLDL/TGs, and decreased HDL. We suggest that HP-, neutrophil- and mononuclear cell-related chronic gastritis could promote systemic inflammation and unfavorable lipid metabolism over time, followed by CVD risk.

This study showed that chronic gastritis was significantly associated with unhealthy behavior, such as less exercise, smoking, alcohol intake, and high BMI. Previous studies have described that exercise-induced nitric oxide (NO) production could contribute to improvement in endothelial function and cardiovascular homeostasis [33,34]. Smoking and high BMI are well-known modifiable factors for CVD [35]. Other studies have demonstrated that weight gain following smoking cessation is associated with a potential risk for CVD [36,37], but large-scale studies showed that weight gain associated with smoking cessation did not outweigh the benefits in terms of CVD risk [38,39]. Regular alcohol intake could elevate blood pressure and is attributed to 16% of hypertension cases [40]. In several studies, blood pressure was reduced after alcohol reduction in patients with hypertension [40,41,42].

There are some limitations that should be acknowledged in this study. This study analyzed subjects who underwent gastroscopy during their health checkups, and there is a potential for selection bias. The relationship among chronic gastritis, leukocyte count and lipid levels could not be conclusively proven due to the cross-sectional design of this study. Hence, longitudinal prospective studies should be conducted to identify the continuous associations among these factors over time. The people enrolled in this study had diverse lifestyle habits, such as exercise rate, smoking, and alcohol intake, which might worsen lipid metabolism. Published data reported that people who drink a large amount of alcohol or lack exercise usually suffer from chronic gastritis [43,44]. In the present study, several factors associated with chronic gastritis and poor lipid profiles overlapped. Hence, it was difficult to make accurate conclusions. To complement these points, we adjusted for potential confounders, including age, sex, BMI, smoking, exercise rate, and alcohol consumption, to clarify the relationship between chronic gastritis and low HDL level in both male and female groups; however, the relationship between these variables remains unclear.

In summary, this large-scale cohort study demonstrated that histological features such as HP infection and monocytic infiltration were associated with increased LDL/VLDL/TGs and decreased HDL as well as elevated leukocyte count in chronic gastritis patients. In multivariate analyses in the female group and the male group, chronic gastritis with mononuclear cells was significantly related to decreased HDL. In the male group, HP infection was also associated with low HDL. Chronic gastritis could be an important factor in the complex mechanisms involved in lipid metabolism. In the future, experimental studies are necessary to clarify the relationships between chronic gastritis and abnormal lipid profiles.

Abbreviations

KBSMC Kangbuk Samsung Medical Center
HP Helicobacter pylori
CVD Cardiovascular disease
LDL Low-density lipoprotein
VLDL Very-low-density lipoprotein
TG Triglyceride
HDL High-density lipoprotein
USS Updated Sydney system
SBP Systolic blood pressure
DBP Diastolic blood pressure
BMI Body mass index
Open in a new tab

Author Contributions

Conceptualization, K.-W.M. and S.K.H.; data curation, D.-H.K., K.-W.M., S.K.H., B.K.S. and J.U.N.; formal analysis, K.-W.M.; investigation, D.-H.K., K.-W.M., S.K.H. and P.C.C.; methodology, D.-H.K., K.-W.M. and W.Y.J.; project administration, D.-H.K., K.-W.M., B.K.S., J.U.N., H.-L.K. and M.J.K.; resources, D.-H.K., K.-W.M. and S.K.H.; software, K.-W.M., J.-Y.M., K.-W.O. and Y.S.K.; supervision, K.-W.M., S.K.H. and H.-L.K.; validation, K.-W.M., B.K.S., Y.H.O., W.Y.J. and S.H.; visualization, K.-W.M.; writing—original draft, K.-W.M.; writing—review and editing, K.-W.M. All authors have read and agreed to the published version of the manuscript.

Ethics Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Institutional Review Board of Kangbuk Samsung Hospital + IRB number 2016-04-044) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The IRB confirmed that informed consent was not necessary in this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  • 1.Takahashi S., Sakai J., Fujino T., Hattori H., Zenimaru Y., Suzuki J., Miyamori I., Yamamoto T.T. The very low-density lipoprotein (VLDL) receptor: Characterization and functions as a peripheral lipoprotein receptor. J. Atheroscler. Thromb. 2004;11:200–208. doi: 10.5551/jat.11.200. [DOI] [PubMed] [Google Scholar]
  • 2.Chan D.C., Barrett P.H.R., Watts G.F. The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Pract Res. Clin. Endocrinol. Metab. 2014;28:369–385. doi: 10.1016/j.beem.2013.10.001. [DOI] [PubMed] [Google Scholar]
  • 3.Zhou X., He L., Wan D., Yang H., Yao K., Wu G., Wu X., Yin Y. Methionine restriction on lipid metabolism and its possible mechanisms. Amino Acids. 2016;48:1533–1540. doi: 10.1007/s00726-016-2247-7. [DOI] [PubMed] [Google Scholar]
  • 4.Zhou H., Liu R. ER stress and hepatic lipid metabolism. Front. Genet. 2014;5:112. doi: 10.3389/fgene.2014.00112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Steinberg D. Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nat. Med. 2002;8:1211–1217. doi: 10.1038/nm1102-1211. [DOI] [PubMed] [Google Scholar]
  • 6.Cullen T.W., Giles D.K., Wolf L.N., Ecobichon C., Boneca I.G., Trent M.S. Helicobacter pylori versus the host: Remodeling of the bacterial outer membrane is required for survival in the gastric mucosa. PLoS Pathog. 2011;7:e1002454. doi: 10.1371/journal.ppat.1002454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Figura N. Helicobacter pylori factors involved in the development of gastroduodenal mucosal damage and ulceration. J. Clin. Gastroenterol. 1997;25(Suppl. S1):S149–S163. doi: 10.1097/00004836-199700001-00025. [DOI] [PubMed] [Google Scholar]
  • 8.Pece S., Giuliani G., Di Leo A., Fumarola D., Antonaci S., Jirillo E. Role of lipopolysaccharide and related cytokines in Helicobacter pylori infection. Recenti Prog. Med. 1997;88:237–241. [PubMed] [Google Scholar]
  • 9.Gilroy D.W., Bishop-Bailey D. Lipid Mediators in Immune Regulation and Resolution. Br. J. Pharmacol. 2019;176:1009–1023. doi: 10.1111/bph.14587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Chimienti G., Russo F., Lamanuzzi B.L., Nardulli M., Messa C., Di Leo A., Correale M., Giannuzzi V., Pepe G. Helicobacter pylori is associated with modified lipid profile: Impact on Lipoprotein(a) Clin. Biochem. 2003;36:359–365. doi: 10.1016/S0009-9120(03)00063-8. [DOI] [PubMed] [Google Scholar]
  • 11.Rasmi Y., Zeynalzadeh J., Shirpoor A., Seyedmohammadzad M., Hajhosseini R. Lipid Profile in Cardiac Syndrome X: Association with Helicobacter pylori. J. Clin. Diagn. Res. 2016;10:BC07–BC09. doi: 10.7860/JCDR/2016/18048.8185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Dixon M.F., Genta R.M., Yardley J.H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 1996;20:1161–1181. doi: 10.1097/00000478-199610000-00001. [DOI] [PubMed] [Google Scholar]
  • 13.Chen T.-P., Hung H.-F., Chen M.-K., Lai H.-H., Hsu W.-F., Huang K.-C., Yang K.-C. Helicobacter pylori Infection is Positively Associated with Metabolic Syndrome in Taiwanese Adults: A Cross-Sectional Study. Helicobacter. 2015;20:184–191. doi: 10.1111/hel.12190. [DOI] [PubMed] [Google Scholar]
  • 14.Gunji T., Matsuhashi N., Sato H., Fujibayashi K., Okumura M., Sasabe N., Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am. J. Gastroenterol. 2008;103:3005–3010. doi: 10.1111/j.1572-0241.2008.02151.x. [DOI] [PubMed] [Google Scholar]
  • 15.Ribaldone D.G., Fagoonee S., Hickman I., Altruda F., Saracco G.M., Pellicano R. Helicobacter pylori infection and ischemic heart disease: Could experimental data lead to clinical studies? Minerva Cardioangiol. 2016;64:686–696. [PubMed] [Google Scholar]
  • 16.Shi Y., Duan J.-Y., Liu D.-W., Qiao Y.-J., Han Q.-X., Pan S.-K., Tang L., Cai G.-Y., Chen X.-M., Liu Z.-S., et al. Helicobacter pylori Infection is Associated with Occurrence of Proteinuria in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis. Chin. Med. J. 2018;131:2734–2740. doi: 10.4103/0366-6999.245269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hosseinzadeh M., Khosravi A., Saki K., Ranjbar R. Evaluation of Helicobacter pylori infection in patients with common migraine headache. Arch. Med. Sci. 2011;7:844–849. doi: 10.5114/aoms.2011.25560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shindler-Itskovitch T., Chodick G., Shalev V., Muhsen K. Helicobacter pylori infection and prevalence of stroke. Helicobacter. 2019;24:e12553. doi: 10.1111/hel.12553. [DOI] [PubMed] [Google Scholar]
  • 19.Ponzetto A., Holton J. Extragastric diseases correlated with Helicobacter pylori. Helicobacter. 2019;24:e12549. doi: 10.1111/hel.12549. [DOI] [PubMed] [Google Scholar]
  • 20.Franceschi F., Leo D., Fini L., Santoliquido A., Flore R., Tondi P., Roccarina D., Nista E.C., Cazzato A.I., Lupascu A., et al. Helicobacter pylori infection and ischaemic heart disease: An overview of the general literature. Dig. Liver Dis. 2005;37:301–308. doi: 10.1016/j.dld.2004.10.015. [DOI] [PubMed] [Google Scholar]
  • 21.Yamaoka Y., Graham D.Y. CagA status and gastric cancer unreliable serological tests produce unreliable data. Gastroenterology. 1999;117:745. doi: 10.1016/S0016-5085(99)70476-2. [DOI] [PubMed] [Google Scholar]
  • 22.Levitzky Y.S., Guo C.-Y., Rong J., Larson M.G., Walter R.E., Keaney J.F., Sutherland P.A., Vasan A., Lipinska I., Evans J.C., et al. Relation of smoking status to a panel of inflammatory markers: The framingham offspring. Atherosclerosis. 2008;201:217–224. doi: 10.1016/j.atherosclerosis.2007.12.058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA. 1998;279:1477–1482. doi: 10.1001/jama.279.18.1477. [DOI] [PubMed] [Google Scholar]
  • 24.Tsang K.W., Lam S.K. Helicobacter pylori and extra-digestive diseases. J. Gastroenterol. Hepatol. 1999;14:844–850. doi: 10.1046/j.1440-1746.1999.01974.x. [DOI] [PubMed] [Google Scholar]
  • 25.Manolakis A., Kapsoritakis A.N., Potamianos S.P. A review of the postulated mechanisms concerning the association of Helicobacter pylori with ischemic heart disease. Helicobacter. 2007;12:287–297. doi: 10.1111/j.1523-5378.2007.00511.x. [DOI] [PubMed] [Google Scholar]
  • 26.Fagoonee S., De Angelis C., Elia C., Silvano S., Oliaro E., Rizzetto M., Pellicano R. Potential link between Helicobacter pylori and ischemic heart disease: Does the bacterium elicit thrombosis? Minerva Med. 2010;101:121–125. [PubMed] [Google Scholar]
  • 27.Kountouras J., Gavalas E., Zavos C., Stergiopoulos C., Chatzopoulos D., Kapetanakis N., Gisakis D. Alzheimer’s disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. Med. Hypotheses. 2007;68:378–388. doi: 10.1016/j.mehy.2006.06.052. [DOI] [PubMed] [Google Scholar]
  • 28.Ross R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med. 1999;340:115–126. doi: 10.1056/NEJM199901143400207. [DOI] [PubMed] [Google Scholar]
  • 29.Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005;352:1685–1695. doi: 10.1056/NEJMra043430. [DOI] [PubMed] [Google Scholar]
  • 30.Shah P.K. Chronic infections and atherosclerosis/thrombosis. Curr. Atheroscler. Rep. 2002;4:113–119. doi: 10.1007/s11883-002-0034-2. [DOI] [PubMed] [Google Scholar]
  • 31.Low J.E., Metz A.L., Mertz T.E., Henry S.P., Knowlton P., Loewen G., Sommers C.S., Robertson D.G., Olszewski B.J., Schroeder R.L. Cardiac hypertrophy in rats after intravenous administration of CI-959, a novel antiinflammatory compound: Morphologic features and pharmacokinetic and pharmacodynamic mechanisms. J. Cardiovasc. Pharmacol. 1995;25:930–939. doi: 10.1097/00005344-199506000-00011. [DOI] [PubMed] [Google Scholar]
  • 32.Takeshita S., Isshiki T., Ochiai M., Ishikawa T., Nishiyama Y., Fusano T., Toyoizumi H., Kondo K., Ono Y., Sato T. Systemic inflammatory responses in acute coronary syndrome: Increased activity observed in polymorphonuclear leukocytes but not T lymphocytes. Atherosclerosis. 1997;135:187–192. doi: 10.1016/S0021-9150(97)00160-3. [DOI] [PubMed] [Google Scholar]
  • 33.Niebauer J., Maxwell A.J., Lin P.S., Wang D., Tsao P.S., Cooke J.P. NOS inhibition accelerates atherogenesis: Reversal by exercise. Am. J. Physiol. Heart Circ. Physiol. 2003;285:H535–H540. doi: 10.1152/ajpheart.00360.2001. [DOI] [PubMed] [Google Scholar]
  • 34.Yang Z., Wang J.M., Chen L., Luo C.F., Tang A.L., Tao J. Acute exercise-induced nitric oxide production contributes to upregulation of circulating endothelial progenitor cells in healthy subjects. J. Hum. Hypertens. 2007;21:452–460. doi: 10.1038/sj.jhh.1002171. [DOI] [PubMed] [Google Scholar]
  • 35.Huang Z., Wu X., Stamler J., Rao X., Tao S., Friedewald W.T., Liao Y., Tsai R., Stamler R., He H. A north-south comparison of blood pressure and factors related to blood pressure in the People’s Republic of China: A report from the PRC-USA Collaborative Study of Cardiovascular Epidemiology. J. Hypertens. 1994;12:1103–1112. doi: 10.1097/00004872-199409000-00017. [DOI] [PubMed] [Google Scholar]
  • 36.Pisinger C., Jorgensen T. Waist circumference and weight following smoking cessation in a general population: The Inter99 study. Prev. Med. 2007;44:290–295. doi: 10.1016/j.ypmed.2006.11.015. [DOI] [PubMed] [Google Scholar]
  • 37.Berlin I. Smoking-induced metabolic disorders: A review. Diabetes Metab. 2008;34:307–314. doi: 10.1016/j.diabet.2008.01.008. [DOI] [PubMed] [Google Scholar]
  • 38.Clair C., Rigotti N.A., Porneala B., Fox C.S., D’Agostino R.B., Pencina M.J., Meigs J.B. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309:1014–1021. doi: 10.1001/jama.2013.1644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Fonseca V., McDuffie R., Calles J., Cohen R.M., Feeney P., Feinglos M., Gerstein H.C., Ismail-Beigi F., Morgan T.M., Pop-Busui R., et al. ACCORD Study Group Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care. 2013;36:2162–2168. doi: 10.2337/dc12-1391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Puddey I.B., Beilin L.J. Alcohol is bad for blood pressure. Clin. Exp. Pharmacol. Physiol. 2006;33:847–852. doi: 10.1111/j.1440-1681.2006.04452.x. [DOI] [PubMed] [Google Scholar]
  • 41.Stewart S.H., Latham P.K., Miller P.M., Randall P., Anton R.F. Blood pressure reduction during treatment for alcohol dependence: Results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction. 2008;103:1622–1628. doi: 10.1111/j.1360-0443.2008.02317.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Rehm J., Gmel G.E., Gmel G., Hasan O.S.M., Imtiaz S., Popova S., Probst C., Roerecke M., Room R., Samokhvalov A.V., et al. The relationship between different dimensions of alcohol use and the burden of disease-an update. Addiction. 2017;112:968–1001. doi: 10.1111/add.13757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Parl F.F., Lev R., Thomas E., Pitchumoni C.S. Histologic and morphometric study of chronic gastritis in alcoholic patients. Hum. Pathol. 1979;10:45–56. doi: 10.1016/S0046-8177(79)80071-4. [DOI] [PubMed] [Google Scholar]
  • 44.Becker H.C. Influence of stress associated with chronic alcohol exposure on drinking. Neuropharmacology. 2017;122:115–126. doi: 10.1016/j.neuropharm.2017.04.028. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES